Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1874-4729|9|1|33-43

ISSN： 1874-4710

Source： Current Radiopharmaceuticals, Vol.9, Iss.1, 2015-11, pp. : 33-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Theranostic Applications of Lutetium-177 in Radionuclide Therapy

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 94-101

Bentham Science Publishers

Access to resources Recommend Favorite

Lutetium-177 Labeled Peptides: The European Institute of Oncology Experience

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 19-32

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease)

By  

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 77-77

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 1, 2015-11 ,pp. : 6-7

Bentham Science Publishers

Access to resources Recommend Favorite

Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with 177Lu and Conjugated to Peptides

By  

Current Radiopharmaceuticals, Vol. 8, Iss. 2, 2015-08 ,pp. : 150-159

Bentham Science Publishers

Access to resources Recommend Favorite